Policy recommendations for implementing registries to minimize over-volunteering in Phase

Lists

Abadie, Roberto, Fisher, Jill A, Mwale, Shadreck ORCID: https://orcid.org/0000-0002-5773-8458, Bompart, Francois and Hirsch, Francois (2025) Policy recommendations for implementing registries to minimize over-volunteering in Phase. Clinical Trials. ISSN 1740-7745

Full text not available from this repository. (Request a copy)

Official URL: https://journals.sagepub.com/doi/10.1177/174077452...

Abstract

Thousands of healthy volunteers enroll in Phase I clinical trials annually, often motivated by financial gain. Some engage in “over-volunteering”—participating in multiple studies simultaneously or ignoring washout periods. While serious adverse effects are rare, the experimental nature of Phase I trials, which for “first-in-human” studies are designed to trigger adverse events under controlled conditions, makes risks uncertain and unpredictable—a concern that might be compounded by concealed trial participation, which may further increase the likelihood of adverse events. Over-volunteering may also distort trial results through undetected drug interactions. To address this, France, Malaysia, and the UK have implemented national registries to track enrollments and enforce washout periods. Private, for-profit registries, like India’s biometric-based system and the US-based Verified Clinical Trials, are used by some clinical research units, mostly private contract research organizations, but their use is not universal and mandatory within countries. Overall, most countries still lack mandatory systems, highlighting the need for broader oversight to protect volunteers and ensure reliable research outcomes. This article discusses the need for and barriers to implementing effective registries and argues that widespread adoption of such registries is critical to protect healthy volunteers from risk of harm while also enhancing trial results’ transparency, reliability, and integrity, thereby contributing to developing safer and more effective drugs.

Item Type:	Article
Identifier:	10.1177/17407745251360649
Subjects:	Medicine and health
Depositing User:	Shadreck Mwale
Date Deposited:	12 Aug 2025 09:21
Last Modified:	12 Aug 2025 09:21
URI:	https://repository.uwl.ac.uk/id/eprint/13979

Actions (login required)

View Item

References

Abadie R. Big Pharma and the Risky World of Human Subjects. Durham, NC: Duke University Press, 2010.

Fisher JA. Adverse Events: Race, Inequality, and the Testing of New Pharmaceuticals. New York: New York University Press, 2020.

Fisher JA, McManus L, Kalbaugh JM, et al. Phase I trial compensation: how much do healthy volunteers actually earn from clinical trial enrollment? Clin Trials 2021; 18(4): 477–487.

Kass NE, Myers R, Fuchs EJ, et al. Balancing justice and autonomy in clinical research with healthy volunteers. Clin Pharmacol Ther 2007; 82(2): 219–227.

Devine EG, Pingitore AM, Margiotta KN, et al. Frequency of concealment, fabrication and falsification of study data by deceptive subjects. Contemp Clin Trials Commun 2021; 21: 100713.

Remy-Jouet I, Eisinger F, Hirsch F. Altruism–but also vulnerability–drive healthy volunteers to take part in clinical research. The Conversation, 8 August, 2022, https://theconversation.com/altruism-but-also-vulnerability-drive-healthy-volunteers-to-take-part-in-clinical-research-184287

Boyce M, Walther M, Nentwich H, et al. TOPS: an internet-based system to prevent healthy subjects from over-volunteering for clinical trials. Eur J Clin Pharmacol 2012; 68(7): 1019–1024.

Verified clinical trials, https://verifiedclinicaltrials.com/

Fisher JA, Bompart F, Montrasio L, et al. A global ethics charter to protect healthy volunteers. Lancet 2024; 404(10453): 651.

Resnik DB, Koski G. A national registry for healthy volunteers in phase 1 clinical trials. JAMA 2011; 305(12): 1236–1237.

Edelblute HB, Fisher JA. Using “clinical trial diaries” to track patterns of participation for serial healthy volunteers in US phase I studies. J Empir Res Hum Res Ethics 2015; 10(1): 65–75.

Bompart F. Healthy volunteers for clinical trials in resource-poor settings: national registries can address ethical and safety concerns. Camb Q Healthc Ethics 2019; 28(1): 134–143.

Elliott C, Abadie R. Exploiting a research underclass in Phase 1 clinical trials. N Engl J Med 2008; 358(22): 2316–2317.

Tools

CORE (COnnecting REpositories)

The University of West London

Policy recommendations for implementing registries to minimize over-volunteering in Phase

Abstract

Actions (login required)

Menu